CRV789
Total Payments
$111,253
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $78,482 | 1 | 0 |
| 2017 | $32,771 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $111,253 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST IN HUMAN TWOPART OPEN LABEL AND RANDOMIZED OR DOUBLE BLIND OR PLACEBO CONTROLLED SINGLE DOSE STUDY OF CSJ137 IN ERYTHROPOIETIN TREATED CHRONIC HEMODIALYSIS PATIENTS WITH FUNCTIONAL IRON DEFICIENCY ANEMIA | Novartis Pharmaceuticals Corporation | $111,253 | 0 |
Top Doctors Receiving Payments for CRV789
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Minneapolis, MN | $111,253 | 2 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $111,253
Product Information
- Type Drug
- Total Payments $111,253
- Total Doctors 0
- Transactions 2
About CRV789
CRV789 is a drug associated with $111,253 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $78,482 was paid across 1 transactions to 0 doctors.
The most common payment nature for CRV789 is "Unspecified" ($111,253, 100.0% of total).
CRV789 is associated with 1 research study, including "A FIRST IN HUMAN TWOPART OPEN LABEL AND RANDOMIZED OR DOUBLE BLIND OR PLACEBO CONTROLLED SINGLE DOSE STUDY OF CSJ137 IN ERYTHROPOIETIN TREATED CHRONIC HEMODIALYSIS PATIENTS WITH FUNCTIONAL IRON DEFICIENCY ANEMIA" ($111,253).